Correlation analysis of serum electrolytes and nutritional status and prognosis in patients with acute exacerbation of chronic obstructive pulmonary disease

doi:10.3877/cma.j.issn.1674-6902.2025.05.031

Abstract

Dong Wang, Caizhou Mo, Ziwen Gu. Correlation analysis of serum electrolytes and nutritional status and prognosis in patients with acute exacerbation of chronic obstructive pulmonary disease[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2025, 18(05): 824-827.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2025.05.031

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2025/V18/I05/824

Figures/Tables 3

References 29

1	Qian Y, Cai C, Sun M, et al. Analyses of factors associated with acute exacerbations of chronic obstructive pulmonary disease: A review[J]. Int J Chron Obstruct Pulmon Dis, 2023, 24(18): 2707-2723.
2	Graul EL, Nordon C, Rhodes K, et al. Temporal risk of nonfatal cardiovascular events after chronic obstructive pulmonary disease exacerbation: A population-based study[J]. Am J Respir Crit Care Med, 2024, 209(8): 960-972.
3	Agustí A, Celli BR, Criner GJ, et al. Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary[J]. Eur Respir J, 2023, 61(4): 2300239.
4	Deep A, Behera PR, Subhankar S, et al. Serum electrolytes in patients presenting with acute exacerbation of chronic obstructive pulmonary disease (COPD) and their comparison with stable COPD patients[J]. Cureus, 2023, 15(4): e38080.
5	Aryal SB, Panthi A, Aryal N, et al. Clinical profile of metabolic derangements in patients with acute exacerbations of chronic obstructive pulmonary disease[J]. J Nepal Health Res Counc, 2025, 22(4): 756-763.
6	Dransfield M, Rowe S, Vogelmeier CF, et al. Cystic fibrosis transmembrane conductance regulator: Roles in chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med, 2022, 205(6): 631-640.
7	Mall MA, Criner GJ, Miravitlles M, et al. Cystic fibrosis transmembrane conductance regulator in COPD: a role in respiratory epithelium and beyond[J]. Eur Respir J, 2023, 61(4): 2201307.
8	Xiao M, Wang X, Wang H, et al. Risk factors for hyponatremia in acute exacerbation chronic obstructive pulmonary disease (AECOPD): a multicenter cross-sectional study[J]. BMC Pulm Med, 2023, 23(1): 39.
9	任成山，王关嵩，钱桂生. 慢性阻塞性肺疾病的成因及其治疗的困惑与希望[J/OL]. 中华肺部疾病杂志(电子版), 2019, 12(2): 127-141.
10	刘欣，刘雪萍，焦玉丁，等. 慢性阻塞性肺疾病并发呼吸衰竭风险预测模型的Meta分析[J/OL]. 中华肺部疾病杂志(电子版), 2025, 18(1): 110-114.
11	田建霞，陈晓香，王继苹. 改良英国医学研究委员会呼吸困难量表评分、慢性阻塞性肺疾病评估测试评分与慢性阻塞性肺疾病患者肺功能的相关性及其对肺动脉高压的预测价值[J]. 实用心脑肺血管病杂志，2018, 26(12): 44-48.
12	中华医学会，中华医学会杂志社，中华医学会全科医学分会，等. 慢性阻塞性肺疾病基层诊疗指南(2018年)[J]. 中华全科医师杂志，2018, 17(11): 856-870.
13	王东梅，韩锋锋. 慢性阻塞性肺疾病呼吸治疗的研究进展[J]. 世界临床药物，2024, 45(3): 244-247, 284.
14	Hawkins NM, Nordon C, Rhodes K, et al. Heightened long-term cardiovascular risks after exacerbation of chronic obstructive pulmonary disease[J]. Heart, 2024, 110(10): 702-709.
15	Swart K, Baak BN, Lemmens L, et al. Risk of cardiovascular events after an exacerbation of chronic obstructive pulmonary disease: results from the EXACOS-CV cohort study using the PHARMO Data Network in the Netherlands[J]. Respir Res, 2023, 24(1): 293.
16	Qi S, Li X, Jiang Y, et al. Analysis of risk factors and development of predictive model for acute myocardial injury in patients with acute exacerbation of chronic obstructive pulmonary disease[J]. J Thorac Dis, 2025, 17(4): 1977-1990.
17	Fredrickson KA, Carver TW. Trauma-related electrolyte disturbances：From resuscitation to rhabdomyolysis[J]. Nutr Clin Pract, 2022, 37(5): 1004-1014.
18	Owusuaa C, Dijkland SA, Nieboer D, et al. Predictors of mortality in chronic obstructive pulmonary disease: a systematic review and meta-analysis[J]. BMC Pulm Med, 2022, 22(1): 125.
19	Fan L, Sun D, Yang J, et al. Association between serum sodium and long-term mortality in critically Ⅲ patients with comorbid chronic obstructive pulmonary disease: Analysis from the MIMIC-Ⅳ database[J]. Int J Chron Obstruct Pulmon Dis, 2022, 17(12): 1143-1155.
20	Balistrieri A, Makino A, Yuan JX. Pathophysiology and pathogenic mechanisms of pulmonary hypertension: role of membrane receptors, ion channels, and Ca^2＋ signaling[J]. Physiol Rev, 2023, 103(3): 1827-1897.
21	Locke BW, Lee JJ, Sundar KM. OSA and chronic respiratory disease：mechanisms and epidemiology[J]. Int J Environ Res Public Health, 2022, 19(9): 5473.
22	Shandell MA, Capatina AL, Lawrence SM, et al. Inhibition of the Na^＋/K^＋-ATPase by cardiac glycosides suppresses expression of the IDO1 immune checkpoint in cancer cells by reducing STAT1 activation[J]. J Biol Chem, 2022, 298(3): 101707.
23	Guerrero-Romero F, Micke O, Simental-Mendía LE, et al. Importance of magnesium status in COVID-19[J]. Biology (Basel), 2023, 12(5): 735.
24	Luan X, Henao Romero N, Campanucci VA, et al. Pulmonary ionocytes regulate airway surface liquid pH in primary human bronchial epithelial cells[J]. Am J Respir Crit Care Med, 2024, 210(6): 788-800.
25	Wang L, Yi R, Wei L, et al. Changes of b2-microglobulin and electrolytes in different stages of COPD and their value in evaluating prognosis[J]. J Med Biochem, 2024, 43(6): 946-954.
26	Huang M, Wang X, Chen Y, et al, Cai L. Role of Na/K-ATPase α1 caveolin-binding motif in adipogenesis[J]. Am J Physiol Cell Physiol, 2024, 327(1): C48-C64.
27	Zhou W, Yu T, Hua Y, et al. Effects of hypoxia on respiratory diseases: perspective view of epithelial ion transport[J]. Am J Physiol Lung Cell Mol Physiol, 2022, 323(3): L240-L250.
28	Trullàs JC, Morales-Rull JL, Casado J, et al. Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial[J]. Eur Heart J, 2023, 44(5): 411-421.
29	Takashi Y, Kawanami D, Fukumoto S. Recent advances in fibroblast growth factor 23-related hypophosphatemic disorders[J]. Curr Opin Endocrinol Diabetes Obes, 2024, 31(4): 170-175.

临床资料	观察组(n＝27)	对照组(n＝55)	t/χ²值	P值
吸烟史[n(%)]	10(37.04)	13(23.64)	1.611	0.204
饮酒史[n(%)]	8(29.63)	11(20.00)	0.943	0.331
糖尿病[n(%)]	5(18.52)	7(12.73)	0.133	0.715
高血压[n(%)]	10(37.04)	14(25.45)	0.174	0.279
机械通气[n(%)]	16(59.26)	26(47.27)	1.041	0.307
Hb[g/L，(±s)]	136.24±5.88	134.88±5.81	0.988	0.328
WBC[×10⁹/L，(±s)]	6.56±1.61	6.38±1.55	0.482	0.632
FVC[L，(±s)]	2.66±0.38	2.75±0.32	1.060	0.295
FEV₁[L，(±s)]	4.06±0.64	4.48±0.47	3.032	0.004
CRP[mg/L，(±s)]	95.16±14.05	89.66±14.32	1.655	0.104
PCT[ng/ml，(±s)]	0.57±0.12	0.66±0.11	1.457	0.152
PaO₂[mmHg，(±s)]	59.74±7.25	60.81±7.35	0.625	0.535
PaCO₂[mmHg，(±s)]	67.35±5.54	65.31±5.62	1.560	0.125
GOLD分级[n(%)]			12.062	0.007
1级	2(7.40)	7(12.73)
2级	8(29.63)	21(38.18)
3级	10(37.04)	26(47.27)
4级	7(25.93)	1(1.82)
APACHEⅡ评分[分，(±s)]	17.13±2.90	15.25±2.35	2.929	0.005
CAT评分[分，(±s)]	21.61±3.25	20.23±2.36	1.966	0.056

临床资料	观察组(n＝27)	对照组(n＝55)	t/χ²值	P值
吸烟史[n(%)]	10(37.04)	13(23.64)	1.611	0.204
饮酒史[n(%)]	8(29.63)	11(20.00)	0.943	0.331
糖尿病[n(%)]	5(18.52)	7(12.73)	0.133	0.715
高血压[n(%)]	10(37.04)	14(25.45)	0.174	0.279
机械通气[n(%)]	16(59.26)	26(47.27)	1.041	0.307
Hb[g/L，(±s)]	136.24±5.88	134.88±5.81	0.988	0.328
WBC[×10⁹/L，(±s)]	6.56±1.61	6.38±1.55	0.482	0.632
FVC[L，(±s)]	2.66±0.38	2.75±0.32	1.060	0.295
FEV₁[L，(±s)]	4.06±0.64	4.48±0.47	3.032	0.004
CRP[mg/L，(±s)]	95.16±14.05	89.66±14.32	1.655	0.104
PCT[ng/ml，(±s)]	0.57±0.12	0.66±0.11	1.457	0.152
PaO₂[mmHg，(±s)]	59.74±7.25	60.81±7.35	0.625	0.535
PaCO₂[mmHg，(±s)]	67.35±5.54	65.31±5.62	1.560	0.125
GOLD分级[n(%)]			12.062	0.007
1级	2(7.40)	7(12.73)
2级	8(29.63)	21(38.18)
3级	10(37.04)	26(47.27)
4级	7(25.93)	1(1.82)
APACHEⅡ评分[分，(±s)]	17.13±2.90	15.25±2.35	2.929	0.005
CAT评分[分，(±s)]	21.61±3.25	20.23±2.36	1.966	0.056

电解质	时相	观察组(n＝27)	对照组(n＝55)	t值	P值
Cl^－	T0	94.45±8.37	98.61±8.45	2.108	0.040
	T1	92.46±7.41	95.57±8.41	1.707	0.093
	T2	95.32±9.58	98.49±9.29	1.441	0.157
Na^＋	T0	118.57±11.64	129.74±12.78	3.952	0.000
	T1	110.65±10.72	124.15±11.84	5.175	0.000
	T2	121.45±11.37	129.58±11.58	3.024	0.004
K^＋	T0	3.72±0.26	3.77±0.28	0.798	0.428
	T1	3.51±0.28	3.74±0.29	3.455	0.001
	T2	3.61±0.45	3.83±0.43	2.111	0.040
Ca^2＋	T0	2.19±0.21	2.11±0.23	1.570	0.122
	T1	2.11±0.24	2.19±0.25	1.399	0.168
	T2	2.13±0.15	2.10±0.26	0.661	0.511

电解质	时相	观察组(n＝27)	对照组(n＝55)	t值	P值
Cl^－	T0	94.45±8.37	98.61±8.45	2.108	0.040
	T1	92.46±7.41	95.57±8.41	1.707	0.093
	T2	95.32±9.58	98.49±9.29	1.441	0.157
Na^＋	T0	118.57±11.64	129.74±12.78	3.952	0.000
	T1	110.65±10.72	124.15±11.84	5.175	0.000
	T2	121.45±11.37	129.58±11.58	3.024	0.004
K^＋	T0	3.72±0.26	3.77±0.28	0.798	0.428
	T1	3.51±0.28	3.74±0.29	3.455	0.001
	T2	3.61±0.45	3.83±0.43	2.111	0.040
Ca^2＋	T0	2.19±0.21	2.11±0.23	1.570	0.122
	T1	2.11±0.24	2.19±0.25	1.399	0.168
	T2	2.13±0.15	2.10±0.26	0.661	0.511

自变量	β	标准误	Wald	P值	OR	95%CI
自变量	β	标准误	Wald	P值	OR	下限	上限
年龄	0.550	0.238	5.357	0.021	1.734	1.088	2.763
FEV₁	－1.670	1.080	2.392	0.122	0.188	0.023	0.563
GOLD分级	1.112	0.864	1.657	0.198	3.041	1.559	16.532
APACHEⅡ评分	0.524	0.247	4.509	0.034	1.689	1.041	2.740
T0 Cl^－	－0.173	0.103	2.833	0.002	0.841	0.688	0.929
T0 Na^＋	－0.104	0.042	6.023	0.114	0.901	0.830	0.979
T1 Na^＋	－0.193	0.072	7.230	0.007	0.825	0.716	0.949
T2 Na^＋	－0.165	0.082	4.045	0.044	0.848	0.723	0.996
T1 K^＋	－6.080	2.678	5.153	0.023	0.002	0.000	0.436
T2 K^＋	－0.788	1.184	0.443	0.506	0.455	0.045	4.629
常量	47.512	19.295	6.064	0.014

Please choose a citation manager

Content to export

Correlation analysis of serum electrolytes and nutritional status and prognosis in patients with acute exacerbation of chronic obstructive pulmonary disease

RichHTML

PDF (PC)

Knowledge

Cited

Abstract

Cite this article

share this article

Figures/Tables 3

References 29

Related Articles 0

Recommended Articles

Metrics

Comments

模态框（Modal）标题

Please choose a citation manager

Content to export

Correlation analysis of serum electrolytes and nutritional status and prognosis in patients with acute exacerbation of chronic obstructive pulmonary disease

RichHTML

PDF (PC)

Knowledge

Cited

Abstract

Cite this article

share this article

Figures/Tables 3

References 29

Related Articles 0

Recommended Articles

Metrics

Comments